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Abstract
Background and aim. Lung cancer is one of the most common tumours and the cause of cancer-related
deaths in European countries. In the past few years, a significant morbidity of chronic obstructive pulmo-
nary disease (COPD) has been noticed in this group of patients. Cigarette smoking is the strongest risk factor
for both conditions. The palliative care of lung cancer patients is often based solely on the tumour symp-
toms' management, whereas some patients would benefit from the combined treatment including the
treatment for COPD. The aim of this study was to evaluate the incidence of COPD in advanced (TNM = IIIB
and IV) non-small cell lung cancer (NSCLC) patients.
Material and methods. The study was a retrospective analysis. One hundred four patients (28 women and
76 men, aged from 47 to 74 years, mean: 63.2 years) with advanced NSCLC were included in the study.
Results. Chronic obstructive pulmonary disease (according to GOLD criteria) was diagnosed in 26 cases
(25%), including 1 mild, 17 moderate and 8 with severe or very severe disease. Chronic obstructive pulmo-
nary disease was significantly more frequent in squamous cell lung carcinoma in comparison to other types
(p = 0.009).
Conclusions. Coexistence of lung cancer and COPD is frequent. Therefore, it is important to consider the
treatment for COPD in palliative care of advanced lung cancer patients.
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Introduction
Lung cancer is the most common tumour in adults
in Europe. Although the trends of lung cancer mor-
tality in the European Union for the next years esti-
mate a reduction in mortality between 2000 and
2015 by 11% [1], the problem still remains wide-
spread and the mean age of the patients gradually
decreases. Smoking is one of the best-documented
risk factors in lung cancer. Moreover, it is also the
strongest risk factor for chronic obstructive pulmo-
nary disease (COPD). The symptoms of advanced stag-
es of both conditions may be very similar: dyspnoea,
chronic cough, weakness, gradual decline in general
health and quality of life. The treatment of chronic
dyspnoea, however, may differ in both conditions.
The results of recent studies demonstrate, that COPD
is underdiagnosed in Poland [2]. Thus, it is likely that
the proportion of patients treated for advanced lung
cancer may also require the proper treatment for
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COPD. The aim of this analysis was to assess the
frequency of simultaneous occurrence of advanced
non-small cell lung cancer (NSCLC) and COPD.
Material and methods
The study was a retrospective analysis of the
medical records of 104 patients with advanced (stage
IIIB and IV) NSCLC hospitalised between 2003 and
2004 at the Department of Pneumonology, Medical
University in Gdansk, Poland. According to WHO
classification, 62 (59.6%) patients had stage IIIB and
42 (40.4%) had stage IV of the disease. The follo-
wing inclusion criteria to the study were used:
— relevant medical history;
— complete case record together with the results
of diagnostic imaging results;
— histopathological documentation of malignancy;
— documented pulmonary function tests documen-
ted.
Gender ratio was 2,71:1 (men vs. women) with
76 (73%) male and 28 (27%) female patients. Age
ranged between 42 and 80 years with the mean age
of 63.8 years (SD = 9.26). Histological examination
confirmed NSCLC in all cases. Histological type was
defined as squamous cell carcinoma (SCC) in 44.2%
(n = 46), adenocarcinoma (AC) in 9.6% (n = 10),
and mixed type in 1% (n = 1). A diagnosis of un-
specified NSCLC was established in 45.2% (n = 47)
of all patients.
Pulmonary function tests were performed with
the “Lungtest 1000” spirometer, MES, Krakow, Po-
land. Staging of the COPD was based on GOLD 2006
guidelines [3]. Computer software “Statistica 7.0 Pl”
StatSoft, Krakow, Poland, was used for Statistical
analysis.
Results
Chronic obstructive pulmonary disease was found
in every fourth of the NSCLC patients (n = 26). There
were 22 (84.6%) male and 4 (15.4%) female pa-
tients in this group. Mean age was 63.2 years (range
47–74 years, SD = 7.55). Eight (31%) of these pa-
tients had severe and very severe COPD, whereas
moderate and mild COPD was found in 17 (65%) of
COPD patients. In 19 out of 26 patients (73%) COPD
coexisted with the SCC (correlation coefficient
r = 0.25, p = 0.009). Histological type was not
defined in 7 remaining cases.
Mean FEV1 was 66.9% and ranged between 25%
and 117% with SD = 18.49. In patients with coexist-
ing COPD mean FEV1 value was 55.9% (range 25–
–95%, SD = 16.82) and in patients without COPD
mean FEV1 was significantly higher at the level of
70.6% (range 34–117%, SD = 17.64); p = 0.003.
Mean FEV1/FVC ratio for the whole population was
0.798 (range 0.47–1.23, SD = 0.1489), while in pa-
tients with and without COPD it was 0.61 (range
0.47–0.70, SD = 0.06) and 0.86 (range 0.70–1.23,
SD = 0.113); respectively; p < 0.00001.
MEF < 50% was found in 70% (n = 73) of all
patients, in 96% (n = 25) of COPD patients and in
61.5% (n = 48) of no-COPD patients; p = 0.027. At
the same time the correlation between MEF < 50%
and simultaneous existence of the COPD and NSCLC
was found (correlation r = 0.33, p = 0.001).
Eighty four (81%) patients admitted to be smok-
ers: 20 (77%) patients from the COPD group and 64
(82%) among the remaining patients; p = 0.03. Mean
number of the pack-years for the whole population
was 39.5; 41.2 for COPD group and 38.9 for no-
COPD patients (correlation r = 0.03, p = 0.76).
The level of haemoglobin was comparable in both
groups — with and without COPD (Table 1).
Discussion
The results of our study demonstrate that every
forth patient with advanced NSCLC cancer may ad-
ditionally suffer from COPD. These results are in con-
cordance with a large Dutch analysis, which assessed
the frequency of COPD in the consecutive cancer
patients registered in the Eindhoven Cancer Registry
between 1995 and 2004. Twelve percent of all can-
cer patients had COPD at the time of diagnosis. In
the group of lung cancer the frequency was even
higher — 30% [4]. In this study a multivariate Cox-
-regression model showed that, COPD was associat-
ed with a significantly worse survival and NSCLC
patients with COPD less frequently underwent sur-
gery, and chemotherapy, whereas radiotherapy was
used more frequently [4]. Another study found COPD
as a predictive factor for severe postradiation pneu-
monitis in patients with locally advanced NSCLC treat-
ed with three-dimensional conformal chemoradio-
therapy [5]. Furthermore, COPD was related to peri-
operative complications after pneumonectomy for
primary lung cancer in Polish series [6].
Coexistence of COPD is an important issue in
every stage of lung cancer. Even in as early stage as
IA the coexistence of COPD is associated with poor-
er prognosis and the higher risk of recurrence after
the complete surgical resection [7]. Recent Serbian
study in patients with resectable tumour showed
that,lung function measured by FEV1 was signifi-
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cantly worse in those with COPD. In addition, oper-
ative morbidity in this group occurred in 50% of
cases [8]. Interestingly, this finding indicates the
necessity of proper diagnosis, because preoperative
bronchodilator therapy may significantly improve
small airways function and postoperative outcomes
in some patients [8].
Dyspnoea is a leading and devastating symptom
in advanced lung cancer [9, 10]. The choice of pal-
liative treatment is related to underlying causes.
Chronic pleural effusion is usually managed with
pleurodesis [11], central bronchial obstruction may
be relieved with the use of chest irradiation [12], or
— in selected patients — with brachytherapy or other
endobronchial strategies [13, 14]. Three cycles of
chemotherapy in patients with relatively good per-
formance status may also be an option [15, 16]. At
the end of life opioids are usually used to palliate
chronic dyspnoea [17]. On the contrary, the use of
oxygen in patients with advanced lung cancer is still
a matter of controversy [18, 19].
Patients with coexisting COPD and advanced lung
cancer may benefit from the bronchodilatator treat-
ment, prolonged oxygen therapy (in cases with de-
creased oxygen saturation) and pulmonary rehabili-
tation [3].
The results of our study (according to our knowl-
edge it is the first assessment of the frequency of
COPD in the advanced lung cancer patients in Po-
land) indicate that the thorough diagnosis of other
respiratory tract diseases, including COPD, may be
of high importance in advanced lung cancer pa-
tients, since the frequency of both diseases is com-
mon in Polish population.
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